Abstract
The development of pharmacologic agents for the treatment of diseases is still challenging, especially in rare inherited arrhythmia syndromes like long and short QT syndrome, Brugada syndrome and catecholaminergic polymorphic ventricular tachycardia. The underling pathophysiologic mechanism of these inherited diseases is in most cases either a gain- or a loss-of-function due to mutations in ion channel genes. Although the biophysical properties of mutant channel subunits are well studied, little is known about the targeting effect of specific pharmacologic agents. In this review, we focus on the therapeutic (in vivo) and the experimental (in vitro) approaches in the most common inherited forms.
Keywords: BrS, brugada syndrome, catecholaminergic polymorphic ventricular tachycardia, CPVT, Long QT syndrome, LQTS, review, short QT syndrome, SQTS, therapeutic approach.
Current Medicinal Chemistry
Title:Pharmacological Targeting in Inherited Arrhythmia Syndromes
Volume: 21 Issue: 11
Author(s): S. Zumhagen, N. Strutz-Seebohm, G. Seebohm and E. Schulze-Bahr
Affiliation:
- Institut für Genetik von Herzerkrankungen (IfGH), Universitätsklinikum Münster (UKM) Albert- Schweitzer-Campus 1, Gebäude D3 D-48149 Münster, Germany.,Germany
Keywords: BrS, brugada syndrome, catecholaminergic polymorphic ventricular tachycardia, CPVT, Long QT syndrome, LQTS, review, short QT syndrome, SQTS, therapeutic approach.
Abstract: The development of pharmacologic agents for the treatment of diseases is still challenging, especially in rare inherited arrhythmia syndromes like long and short QT syndrome, Brugada syndrome and catecholaminergic polymorphic ventricular tachycardia. The underling pathophysiologic mechanism of these inherited diseases is in most cases either a gain- or a loss-of-function due to mutations in ion channel genes. Although the biophysical properties of mutant channel subunits are well studied, little is known about the targeting effect of specific pharmacologic agents. In this review, we focus on the therapeutic (in vivo) and the experimental (in vitro) approaches in the most common inherited forms.
Export Options
About this article
Cite this article as:
Zumhagen S., Strutz-Seebohm N., Seebohm G. and Schulze-Bahr E., Pharmacological Targeting in Inherited Arrhythmia Syndromes, Current Medicinal Chemistry 2014; 21(11) . https://dx.doi.org/10.2174/0929867320666131119142839
DOI https://dx.doi.org/10.2174/0929867320666131119142839 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Artificial Intelligence for Epigenetics: Towards Personalized Medicine
Current Medicinal Chemistry Strain Imaging Echocardiography: What Imaging Cardiologists Should Know
Current Cardiology Reviews Phytochemical Therapies in Vascular Functioning: A Molecular Approach
Current Vascular Pharmacology The Role of Transesophageal Echocardiography in the Intraoperative Period
Current Cardiology Reviews Pathogenesis of Age-Related Cataract: A Systematic Review of Proteomic Studies
Current Proteomics Recent Updates on Current and Upcoming Biomarkers for Cardiovascular Diseases
Current Pharmaceutical Design Benefits of L-Arginine on Cardiovascular System
Mini-Reviews in Medicinal Chemistry Gender Differences in the Treatment of Ischemic Heart Disease
Current Pharmaceutical Design AMP-Activated Protein Kinase (AMPK): Regulation of Metabolic Gene Expression
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Von Willebrand Factor and Cardiovascular Disease: From a Biochemical Marker to an Attractive Therapeutic Target
Current Vascular Pharmacology Coinhibitory Molecule PD-1 as a Therapeutic Target in the Microenvironment of Multiple Myeloma
Current Cancer Drug Targets The Therapeutic Potential of Hepatocyte Growth Factor for Myocardial Infarction and Heart Failure
Current Pharmaceutical Design Lost in Translation: What is Limiting Cardiomyoplasty and Can Tissue Engineering Help?
Current Stem Cell Research & Therapy Adaptors in Toll-Like Receptor Signaling and their Potential as Therapeutic Targets
Current Drug Targets Nutrition, Nitrogen Requirements, Exercise and Chemotherapy-Induced Toxicity in Cancer Patients. A puzzle of Contrasting Truths?
Anti-Cancer Agents in Medicinal Chemistry HLA-G - From Fetal Tolerance to a Regulatory Molecule in Inflammatory Diseases
Current Immunology Reviews (Discontinued) Therapeutic Applications of Calcium Metabolism Modulation in Heart Disease
Medicinal Chemistry Impact of Ultrasound Contrast Agents in Echocardiographic Assessment of Ischemic Heart Disease
Recent Patents on Cardiovascular Drug Discovery The Progress Towards the Development of DHQO Derivatives and Related Analogues with Inotropic Effects
Mini-Reviews in Medicinal Chemistry Contribution of Catecholamine Reactive Intermediates and Oxidative Stress to the Pathologic Features of Heart Diseases
Current Medicinal Chemistry